Press Releases
February 2, 2023
Appointment of Dr. David John Jeans CBE as HistoIndex’s Non-Executive Chairman
SINGAPORE, Jan. 10, 2023 /PRNewswire/ — The Board of Directors (the “Board”) of HistoIndex…
October 14, 2022
HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial
SINGAPORE, July 29, 2022/ — HistoIndex, a global leading artificial intelligence digital pathology…
May 9, 2022
HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials
This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine…
October 20, 2021
HistoIndex and Galecto to Collaborate on Galecto’s Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology
HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has announced…
August 18, 2021
HistoIndex’s Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet’s NASH FASCINATE-2 Phase 2b Clinical Trial
Singapore, 18 August 2021 – HistoIndex, a global leading artificial intelligence (AI) digital pathology…
June 25, 2021
HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo
HistoIndex’s Second Harmonic Generation (SHG) stain-free digital pathology platform has shown marked…
January 25, 2021
HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)
Assessing the morphological and architectural changes in collagen fibers with the platform…
May 25, 2020
HistoIndex’s AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China
Singapore medtech company HistoIndex’s AI-based stain-free digital pathology platform has long been…
November 10, 2019
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Histopathological Features
SINGAPORE, 9 NOVEMBER 2019 – qFIBS, a novel automated algorithm developed by HistoIndex,…
October 26, 2019
HistoIndex Announces Global Partnerships to Expand AI-Based Digital Pathology Platform as a Drug Discovery Tool in Preclinical Studies for Nonalcoholic Steatohepatitis (NASH)
The Singapore-based company has fostered partnerships with pharmaceutical and biotech companies, Contract…
August 20, 2019
[By Newcastle University] LITMUS – Progress towards diagnosing and better treating liver disease
– A pioneering European research project, designed to develop new diagnostic tests…
August 7, 2019
HistoIndex and ILBS Launch Centre of Excellence in New Delhi for Advanced Diagnostics and Clinical Research on Nonalcoholic Steatohepatitis (NASH)
The Center of Excellence aims to enhance NASH diagnostics and clinical trials…